Hims & Hers misses revenue estimates as strategy shift hits sales
Key takeaways
- The Hims & Hers said that while its transition to branded GLP-1 weight-loss drugs from compounded versions introduces restructuring costs, it expects to return to profits in 2027.
- “We historically had focused on operating cash flow, which remained positive.
- Hims has seen record levels of engagement and traffic on its platforms after pivoting to FDA-approved drugs, like Novo Nordisk’s Wegovy, Okupe said.
Why this matters: local context for readers following news across Pakistan and the region.
Add ARY News on Google AAResize Hims & Hers Health missed Wall Street estimates for first-quarter revenue and posted a surprise loss on Monday, as the telehealth company’s shift toward branded GLP-1 weight-loss drugs pressured its margins and domestic sales.
Shares of the Hims & Hers company fell more than 12% in extended trading to $25.55, even as Hims raised its full-year revenue forecast on expectations that a partnership with Novo Nordisk and international growth will help boost sales.
The Hims & Hers said that while its transition to branded GLP-1 weight-loss drugs from compounded versions introduces restructuring costs, it expects to return to profits in 2027.